Xenetic Biosciences Strengthens Technology Patent Portfolio
June 09, 2014 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference
May 29, 2014 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics,...
Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update
May 21, 2014 08:07 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics,...
Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
May 12, 2014 16:01 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors
May 05, 2014 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today...
Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update
April 16, 2014 07:01 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- Xenetic BioSciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology...
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
April 07, 2014 07:01 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
April 04, 2014 08:11 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., April 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today...
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA
March 04, 2014 08:13 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Announces Ticker Symbol Change to XBIO
February 14, 2014 07:01 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...